Vicore Pharma Holding AB
Rapporter
Visar 3 grupper
-
Kvartalsrapport Q1 2026
ENSVFinancial Performance
- Revenue for the first quarter of 2026 was SEK 0.6 million, compared to SEK 0.9 million in the same period of 2025.
- Operating loss for the quarter amounted to SEK 123.8 million, compared to SEK 91.5 million in Q1 2025.
- Loss for the period was SEK 108.6 million (Q1 2025: SEK 111.5 million).
- Cash, cash equivalents, and short-term investments…
-
Bokslutskommuniké Q4 2025
ENSVFinancial Performance
- Revenue for the year ended December 31, 2025, was SEK 3.8 million (2024: SEK 109.4 million).
- Operating loss for the year ended December 31, 2025, was SEK 452.4 million (2024: SEK 194.2 million).
- Loss for the period was SEK 477.5 million (2024: SEK 168.6 million).
- Loss per share, before and after dilution, was SEK 1.99 (2024: SEK 1.23).
- Cash,…